StocksMedium•10 November 2026•
1 min read
Humacyte Symvess Sales Surge 151% in Q3 2026 Amid Commercial Expansion
Key Facts
1Symvess sales in Q3 totaled $1.0 million, representing a 151% increase over the second quarter.
2Commercial momentum continued into Q4, with October 2026 sales reaching $0.8 million.
Humacyte Symvess sales totaled $1.0 million in the third quarter of 2026. GlobeNewswire reported that this figure represents a 151% increase over the second quarter. The company attributed the revenue growth to the accelerating commercial adoption of the product.
Commercial momentum continued into the fourth quarter of 2026, with sales in October reaching $0.8 million. Regarding market performance, HUMA shares closed at $0.4552 on November 9, 2026, after reaching a session high of $0.4934.